Eupafolin inhibits breast cancer cell proliferation and induces apoptosis by inhibiting the PI3K/Akt/mTOR pathway

Eupafolin is a flavonoid extracted from common sage. Previous studies have reported that Eupafolin has antioxidant, anti-inflammatory, and anti-tumor effects. However, its role in breast cancer remains unclear. The present study investigated the effects and underlying mechanism of action of Eupafolin using breast cancer cell lines. The effects of Eupafolin on breast cancer cell proliferation, migration, apoptosis and the cell cycle were determined. Cell viability and Transwell assays, reverse transcription-quantitative PCR, flow cytometry and western blot analysis were used in this study. The data showed that the proliferation, migration and invasion ability of EO771 cells treated with Eupafolin was significantly decreased, and the apoptosis rate was increased compared with that of the control. The protein levels of Bax and cleaved caspase 3 increased, whereas that of Bcl-2 decreased. In addition, Eupafolin treatment also caused the proliferation of breast cancer cells to be arrested at the G(0)/G(1) phase. Furthermore, results from western blotting indicated that Eupafolin treatment decreased the protein levels of p-PI3K, p-Akt and p-mTOR. Taken together, the present findings demonstrate that Eupafolin has a significant inhibitory effect on the proliferation of EO771 cells, inhibits cell migration and invasion, and promotes cell apoptosis, thereby causing G(0)/G(1) phase arrest, at least partially through the PI3K/Akt/mTOR signaling pathway. Therefore, the findings provide novel insights regarding the use of Eupafolin for the treatment of breast cancer.

Automated summary

In this study, Eupafolin was shown to significantly reduce the proliferation, migration, and invasion abilities of EO771 cells, increase apoptosis, and cause G(0)/G(1) phase arrest through the PI3K/Akt/mTOR signaling pathway. These findings provide new insights into the potential use of Eupafolin for breast cancer treatment.